# Sildenafil

Drug · id `cardio:sildenafil` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Sildenafil citrate; Revatio

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Sildenafil, in the form sold as Revatio, is a phosphodiesterase 5 (PDE5) inhibitor. The US label for pulmonary arterial hypertension (PAH) (WHO Group I) lists, in adults, improving exercise ability and delaying clinical worsening and, separately, in pediatric patients 1 to 17 years old, improving exercise ability. This page covers the pulmonary arterial hypertension use. Sildenafil also has a separate US label for erectile dysfunction, which this page does not describe. The label says sildenafil inhibits an enzyme, PDE-5, in the smooth muscle of the lung blood vessels.

## Technical summary

RxNorm ingredient 136411 (RxNorm also holds 221161, sildenafil citrate). MeSH D000068677 is named Sildenafil Citrate, with Sildenafil among its entry terms (a lookup on 2026-11-18, hash only), and carries no scope note, so it is recorded as an exact match for identity only. The openFDA label record for Revatio lists a UNII for the citrate, which is not recorded for the substance. RxClass lists the established pharmacologic class Phosphodiesterase 5 Inhibitor, so the record is filed under the PDE5 inhibitor page for pulmonary hypertension. The label read is the Viatris Specialty LLC label for Revatio, applications NDA203109, NDA022473 and NDA021845, effective 2024-12-18 in openFDA. The adult and pediatric statements sit in separate claims and contexts. The Viagra label (NDA020895, Viatris Specialty LLC, effective 2023-11-17) was read only for its first indication sentence. A maternal atlas page for sildenafil exists and is a separate record. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Pediatric patients 1 to 17 years old with pulmonary arterial hypertension, as described in the US label of Revatio

Recipient: Child; Population: Pediatric patients 1 to 17 years old with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Pediatric patients 1 to 17 years old, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of Revatio separately lists treating pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients 1 to 17 years old, to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, a measure of pulmonary hemodynamics.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Child; Population: Pediatric patients 1 to 17 years old with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Pediatric patients 1 to 17 years old, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim is tied to the Revatio label for children aged 1 to 17 years. It says nothing about newborns or children under 1 year. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The adult indication sits in a separate claim.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Revatio (sildenafil citrate tablets, oral suspension and injection), Viatris Specialty LLC label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id 3bb9363e-b28d-4019-8aae-539233dca214 (manufacturer Viatris Specialty LLC, application NDA203109, NDA022473 and NDA021845), returned on 2026-11-18. The label text is dated 2024-12-18 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. An older Revatio label from Pfizer Laboratories (set id f158fe10, effective 2023-01-27) was not used.) <https://api.fda.gov/drug/label.json?search=set_id:%223bb9363e-b28d-4019-8aae-539233dca214%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:36Z. Source state: Current. Version fingerprint: 26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb.
     How it applies: Application number of the label read, NDA203109.
  2. Background: openFDA drug label record for Revatio (sildenafil citrate tablets, oral suspension and injection), Viatris Specialty LLC label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id 3bb9363e-b28d-4019-8aae-539233dca214 (manufacturer Viatris Specialty LLC, application NDA203109, NDA022473 and NDA021845), returned on 2026-11-18. The label text is dated 2024-12-18 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. An older Revatio label from Pfizer Laboratories (set id f158fe10, effective 2023-01-27) was not used.) <https://api.fda.gov/drug/label.json?search=set_id:%223bb9363e-b28d-4019-8aae-539233dca214%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:36Z. Source state: Current. Version fingerprint: 26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb.
     How it applies: Effective date of the label text read, 20241218.
  3. Supports: openFDA drug label record for Revatio (sildenafil citrate tablets, oral suspension and injection), Viatris Specialty LLC label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id 3bb9363e-b28d-4019-8aae-539233dca214 (manufacturer Viatris Specialty LLC, application NDA203109, NDA022473 and NDA021845), returned on 2026-11-18. The label text is dated 2024-12-18 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. An older Revatio label from Pfizer Laboratories (set id f158fe10, effective 2023-01-27) was not used.) <https://api.fda.gov/drug/label.json?search=set_id:%223bb9363e-b28d-4019-8aae-539233dca214%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T22:01:36Z. Source state: Current. Version fingerprint: 26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb.
     How it applies: Label passage quoted in the research quote table (Q-K30-SIL-LB-05, Q-K30-SIL-LB-06).

## Context: Adults with pulmonary arterial hypertension, as described in the US label of Revatio

Recipient: Adult; Population: Adults with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)

### The US label of Revatio (sildenafil citrate, Viatris Specialty LLC, applications NDA203109, NDA022473 and NDA021845; the version dated 2024-12-18 in openFDA) lists treating pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adults with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)
- Limitations: This claim is tied to the Revatio label for pulmonary arterial hypertension. The substance also has separate labels for other uses, which are not recorded here. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a pediatric use, which sits in a separate claim.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Revatio (sildenafil citrate tablets, oral suspension and injection), Viatris Specialty LLC label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id 3bb9363e-b28d-4019-8aae-539233dca214 (manufacturer Viatris Specialty LLC, application NDA203109, NDA022473 and NDA021845), returned on 2026-11-18. The label text is dated 2024-12-18 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. An older Revatio label from Pfizer Laboratories (set id f158fe10, effective 2023-01-27) was not used.) <https://api.fda.gov/drug/label.json?search=set_id:%223bb9363e-b28d-4019-8aae-539233dca214%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:36Z. Source state: Current. Version fingerprint: 26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb.
     How it applies: Application number of the label read, NDA203109.
  2. Background: openFDA drug label record for Revatio (sildenafil citrate tablets, oral suspension and injection), Viatris Specialty LLC label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id 3bb9363e-b28d-4019-8aae-539233dca214 (manufacturer Viatris Specialty LLC, application NDA203109, NDA022473 and NDA021845), returned on 2026-11-18. The label text is dated 2024-12-18 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. An older Revatio label from Pfizer Laboratories (set id f158fe10, effective 2023-01-27) was not used.) <https://api.fda.gov/drug/label.json?search=set_id:%223bb9363e-b28d-4019-8aae-539233dca214%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:36Z. Source state: Current. Version fingerprint: 26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb.
     How it applies: Effective date of the label text read, 20241218.
  3. Supports: openFDA drug label record for Revatio (sildenafil citrate tablets, oral suspension and injection), Viatris Specialty LLC label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id 3bb9363e-b28d-4019-8aae-539233dca214 (manufacturer Viatris Specialty LLC, application NDA203109, NDA022473 and NDA021845), returned on 2026-11-18. The label text is dated 2024-12-18 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. An older Revatio label from Pfizer Laboratories (set id f158fe10, effective 2023-01-27) was not used.) <https://api.fda.gov/drug/label.json?search=set_id:%223bb9363e-b28d-4019-8aae-539233dca214%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T22:01:36Z. Source state: Current. Version fingerprint: 26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb.
     How it applies: Label passage quoted in the research quote table (Q-K30-SIL-LB-03, Q-K30-SIL-LB-04).

## Connected pages

- Sildenafil is a phosphodiesterase 5 inhibitor (FDA established pharmacologic class in RxClass): PDE5 inhibitors for pulmonary hypertension (`cardio:pde5-inhibitors-for-pulmonary-hypertension`)
- FDA label lists pulmonary arterial hypertension (WHO Group I) in adults, to improve exercise ability and delay clinical worsening, as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-revatio-label-indications` and its context]
- FDA label separately lists pulmonary arterial hypertension in pediatric patients 1 to 17 years old as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-revatio-label-paediatric` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: c8b03238726a3a5664c5c6bc1af234a820ad820ea08662ca335fe75f0146eab3
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
